Approach

Summary

Licensing status

Publication and contact information

Disease models

Phlorizin-pretreated mice with streptozotocin-induced diabetes as models of diabetic nephropathy

Phlorizin pretreatment in mice with streptozotocin-induced diabetes make them useful as models to help identify new treatments for diabetic nephropathy. In mice, high doses of streptozotocin induce diabetes but also cause acute kidney injury (AKI), which makes the mice unsuitable as models of diabetic nephropathy. In the kidneys of mice given a high dose of streptozotocin, AKI markers were associated with downregulation of solute carrier family 2 facilitated glucose transporter member 2 (Slc2a2; Glut2). In mouse models of streptozotocin-induced diabetes, pretreatment with the competitive sodium-glucose cotransporter 2 (SGLT2) inhibitor phlorizin increased Glut2 levels and decreased both renal uptake of streptozotocin and consequent AKI compared with vehicle pretreatment. Next steps could include confirming that the mice develop diabetic nephropathy and using them to evaluate therapeutic candidates.

SciBX 6(36); doi:10.1038/scibx.2013.1010
Published online Sept. 19, 2013

Unpatented; unlicensed

Brouwers, B. et al. J. Biol. Chem.; published online Aug. 11, 2013;
doi:10.1074/jbc.M113.469486
Contact: Jeroen Declercq, Catholic University Leuven, Leuven, Belgium
e-mail:

jeroen.declercq@med.kuleuven.be